Keywords: USA, Medicare, Dendreon, Provenge, Cost-benefit debate
USA’s Medicare review of Dendreon’s prostate cancer vaccine Provenge renews medical cost-benefit debate, says Washington Post
Article | 10 November 2010
The US Centers for Medicare and Medicaid Services (CMS), which dictates what treatments the federal health-insurance program for the elderly ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
